Efficacy and safety of CHAG regimen in elderly patients with acute myeloid leukemia

Abstract

Objective To evaluate the clinical value of combination of arabinosylcytosine, homoharringtonine, aclarubicin and granulocyte colony stimulating factor (CHAG) chemotherapy regimen in the elderly patients with acute myeloid leukemia. Methods Sixty elderly patients with acute myeloid leukemia treated in Jiaozuo People’s Hospital from January 2015 to March 2018 were selected and divided into study group (n=30) and control group (n=30) by random number table method. Patients in the study group were treated with CHAG chemotherapy regimen, and patients in the control group were treated with arabinosylcytosine, aclarubicin and granulocyte colony stimulating factor chemotherapy regimen. The short-term efficacy and follow-up results of the two groups were recorded. Results The total effective rate of clinical treatment in the study group was 93.33% (28/30), higher than the 73.33% (22/30) in the control group (P<0.05). During the follow-up period, the mortality rate and recurrence rate in the observation group were 3.33% (1/30) and 10.00% (3/30), respectively; and they were 23.33% (7/30) and 33.33% (10/30) in the control group; there were significant differences in the two indexes between the two groups (P<0.05). Conclusions CHAG chemotherapy is effective in the treatment of elderly patients with acute myeloid leukemia. Key words: Acute myeloid leukemia; Arabinosylcytosine, homoharringtonine, aclarubicin and granulocyte colony stimulating factor regimen; Effectiveness; Safety